Q-omics provides the consensus-scored PPP1R12A profile across patient tissues and cancer cell-line models. PPP1R12A expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, PPP1R12A is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, PPP1R12A protein abundance shows 27,981 significant protein co-abundance associations, with the highest sampling consensus in UCEC. Together, these results highlight UCS, HNSC, and UCEC as cancer lineages where PPP1R12A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PPP1R12A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PPP1R12A survival associations across molecular data types. PPP1R12A RNA expression shows survival associations in the most cancer types (26), followed by mutation status (7) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PPP1R12A RNA expression–survival associations across cancer types. High PPP1R12A expression shows unfavorable associations in UVM, MESO and ESCA, but favorable associations in UCS, KIRC and SKCM. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .008). Together, the overview and detailed table identify UCS as the clearest survival context for PPP1R12A RNA expression.
This table summarizes PPP1R12A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for PPP1R12A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PPP1R12A shows lower tumor expression in BLCA, THCA, UCEC and BRCA and higher tumor expression in HNSC and LIHC. The HNSC box plot shows higher PPP1R12A RNA expression in tumor versus normal tissue (log2 FC = +0.725, t-test p < 0.001).
This table shows molecular features associated with PPP1R12A in patient tissues and cancer cell lines. In patient samples, PPP1R12A shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set. In cancer cell lines, PPP1R12A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and LIVER.
